Araceli Biosciences Expands Access to Advanced Drug Discovery Technologies in Europe

PORTLAND, OR – Dec 11, 2025 — Araceli Biosciences is introducing its Endeavor® Ultra High-Content Imaging platform in Switzerland for the first time by collaborating with Idorsia Pharmaceuticals Ltd. Endeavor has been installed at Idorsia’s cutting-edge research facility in Basel to support their innovative approaches to drug discovery and accelerate complex biological screening.

Driving Innovation in High-Throughput Screening

The Endeavor® Ultra platform combines high-speed imaging with ClaireRT™ real-time monitoring to streamline workflows and deliver actionable data faster. This technology is designed to help researchers advance promising drug candidates with greater efficiency and precision.

“We’re excited to explore how this technology can elevate our screening efforts,” said Urs Lüthi, Head of Screening & Lead Discovery. “The capabilities it brings fit directly into our mission to discover, validate, and advance promising drug candidates.”

Showcasing Technology in a Real-World Setting

The platform is now operational within Idorsia’s research environment, providing a unique opportunity for European scientists to see how advanced imaging and AI-driven analysis can transform discovery programs. Demonstrations can be scheduled on-site in Switzerland for those interested in exploring its capabilities.

About Araceli Biosciences

Araceli Biosciences is dedicated to accelerating drug discovery through innovations in high-content imaging and AI-powered analytics. With its flagship Endeavor® system and Clairvoyance software, Araceli empowers scientists to generate meaningful insights across a wide range of biological applications.

To arrange a visit or request additional information, please reach out. We’re happy to coordinate a personalized demo at Idorsia’s facility.